Transgene Biotek Ltd
₹ 4.50
-0.22%
05 Feb
- close price
About
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
Key Points
- Market Cap ₹ 34.1 Cr.
- Current Price ₹ 4.50
- High / Low ₹ 11.6 / 3.91
- Stock P/E
- Book Value ₹ 1.43
- Dividend Yield 0.00 %
- ROCE -2.07 %
- ROE -5.98 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 39.1 to 15.9 days.
Cons
- Stock is trading at 3.15 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -37.7% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.01 | 0.98 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | -0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.24 | |
| 15.83 | 2.81 | 1.90 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.08 | |
| Operating Profit | -0.82 | -1.83 | -1.60 | -1.14 | -2.56 | -2.10 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -0.84 |
| OPM % | -5.46% | -186.73% | -533.33% | -633.33% | -914.29% | -1,750.00% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -350.00% | |
| -0.00 | -114.37 | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | |
| Interest | 0.20 | -0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.09 |
| Depreciation | 1.02 | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.08 |
| Profit before tax | -2.04 | -133.42 | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.23 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 13.98% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | |
| -2.03 | -133.41 | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.23 | |
| EPS in Rs | -0.31 | -17.61 | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.03 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 27% |
| 3 Years: | 11% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 25% |
| TTM: | 88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 3% |
| 3 Years: | 6% |
| 1 Year: | -58% |
| Return on Equity | |
|---|---|
| 10 Years: | -17% |
| 5 Years: | -35% |
| 3 Years: | -38% |
| Last Year: | -6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 256.17 | 130.20 | 115.62 | 98.67 | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 | -65.06 | -64.94 |
| 22.46 | 13.06 | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14.00 | 13.95 | |
| 24.22 | 139.32 | 137.95 | 123.27 | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 117.29 | |
| Total Liabilities | 368.62 | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 142.07 |
| 197.80 | 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 8.18 | |
| CWIP | 0.29 | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.10 | 0.10 | 0.10 | 0.10 |
| 170.53 | 177.48 | 180.08 | 171.75 | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134.00 | 133.79 | |
| Total Assets | 368.62 | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 142.07 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.00 | -2.11 | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | -0.00 | -0.00 | |
| -15.35 | 1.45 | -4.57 | -6.47 | -0.00 | 3.05 | 1.74 | -0.00 | -0.03 | -0.10 | -0.01 | -0.00 | |
| 2.41 | 0.60 | 1.03 | -0.00 | -0.00 | -2.37 | -0.00 | -0.20 | -0.00 | -0.00 | -0.00 | -0.00 | |
| Net Cash Flow | 0.06 | -0.05 | -0.02 | -0.00 | 0.02 | 0.05 | -0.00 | -0.06 | -0.01 | -0.00 | -0.01 | -0.00 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 448.16 | 6,797.19 | 19,953.33 | 3,325.56 | 13.04 | 30.42 | 52.14 | 21.47 | 40.56 | 60.83 | 15.87 | |
| Inventory Days | 6.40 | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | |||||
| Days Payable | 437.74 | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | |||||
| Cash Conversion Cycle | 16.82 | -19,072.18 | 19,953.33 | 3,325.56 | 13.04 | -4,623.33 | -3,111.19 | -1,316.86 | 40.56 | -982.02 | 15.87 | |
| Working Capital Days | 51.07 | 648.06 | 1,399.17 | 2,108.89 | -1,864.11 | -21,717.50 | -36,239.29 | -14,514.12 | -5,231.67 | -7,725.83 | -1,777.39 | |
| ROCE % | -0.53% | -6.48% | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% |
Documents
Announcements
- The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company, For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards) Rules, 2015. Limited Review Report On The Unaudited Standalone And Consolidated Financial Results Of The Company, For The Quarter Ended 31.12.2024 Has Also Been Approved. 24 Jan
-
Board Meeting Outcome for Outcome Of Board Meeting - Scrip Code 526139
24 Jan - Board approved financial results and funding proposal.
-
Statement Of Deviation & Variation
20 Jan - Non-applicability of Regulation 32(1) for Q4 2024.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 20 Jan
-
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 24"January 2025
16 Jan - Board meeting on January 24 to approve Q4 results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]